Business Context and Reporting Period
Genprex, Inc. (GNPX), an emerging growth company incorporated in Delaware, filed this Form 8-K on February 11, 2020. The report details the entry into a material definitive agreement with the University of Pittsburgh regarding diabetes gene therapy.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Agreements
Exclusive License Agreement with University of Pittsburgh
- Effective Date: February 11, 2020.
- Scope: Genprex received a worldwide, exclusive license for patents and technology related to diabetes gene therapy, plus a non-exclusive license for related know-how.
- Field of Use: Diabetes therapy.
- Commercialization Obligations: Genprex must use diligent and commercially reasonable efforts to bring the technology to market and achieve specified milestones within set time periods.
- Reporting: Annual progress reports are required, with quarterly manufacturing and sales reports commencing in the year of the first commercial sale.
Financial Terms and Obligations
While specific dollar amounts are not disclosed in the summary text, Genprex agreed to the following payment structures:
- Initial license fee.
- Annual maintenance fees.
- Running royalties and minimum annual royalties.
- Share of non-royalty sublicense income.
- Certain milestone payments.
- Reimbursement for patent prosecution expenses incurred before and after the effective date.
Term: The agreement lasts until the later of 20 years after the first commercial sale or the expiration of the last valid patent claim.
Risks, Contingencies, and Termination
- Termination by University of Pittsburgh: Permitted in cases of uncured default, failure to meet milestones, practice of rights outside the diabetes field, bankruptcy, or insolvency of Genprex.
- Termination by Genprex: Permitted with six months' prior written notice and payment of all accrued amounts.
- Government Rights: Licenses are subject to U.S. government rights, which may hold a nonexclusive, paid-up license to practice the inventions.
- University Rights: The University retains a royalty-free, nonexclusive right to use the technology for non-commercial education and research.
Investor Verification Checklist
- Review Exhibit 10.1 for the specific dollar amounts of the initial license fee, milestone payments, and royalty rates.
- Verify the specific milestones and timeframes required to maintain the license.
- Assess Genprex's current cash position to determine its ability to fund the required payments and development efforts.
- Confirm the status of the underlying patents and their expiration dates.